GlassScriptPhysician profile
Maria Valdes
NPI 1902890809
$4,832.25
in general payments reported to CMS, 2019-2025
29 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $553 · 2021: $618 · 2022: $845 · 2023: $963 · 2024: $752 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,623.19 | 2019-2024 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $550.16 | 2019-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $529.18 | 2019-2025 | Epclusa |
| Celgene Corporation | $375.41 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $368.88 | 2024-2025 | Rezdiffra |
| Janssen Biotech, INC. | $237.42 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.81 | 2019-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $171.26 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $94.93 | 2020-2024 | Linzess |
| Boston Scientific Corporation | $79.27 | 2023-2024 | Advanix Biliary, Exalt Model D, Autotome Rx 49 |
| Amgen INC. | $62.92 | 2019 | |
| Intuitive Surgical, INC. | $55.75 | 2021-2023 | Da Vinci Surgical System |
| Avanir Pharmaceuticals, INC. | $52.52 | 2019 | |
| Redhill Biopharma INC. | $51.50 | 2020-2021 | |
| Shire North American Group INC | $48.05 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $39.73 | 2019-2023 | Ocaliva |
| Acorda Therapeutics, INC | $34.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.74 | 2024 | Xarelto |
| Heraeus Medical, LLC. | $28.58 | 2022 | |
| Vivus LLC | $22.87 | 2024 | Pancreaze |
| Promius Pharma LLC | $20.01 | 2019 | |
| Indivior INC. | $19.72 | 2019 | |
| Integra Lifesciences Corporation | $18.90 | 2023 | Integra, Surgimend, Omnigraft |
| Tris Pharma INC | $18.46 | 2020 | |
| Merck Sharp & Dohme LLC | $18.15 | 2019 | |
| Pfizer INC. | $16.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.60 | 2021 | |
| Ge Healthcare | $12.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Valdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.